Placebo ODT: Clinical Trials

5 trials of Placebo ODT, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 1 recruiting. 5 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Terminated 2, Recruiting 1
Phase 31Completed 1

Follow Placebo ODT: new trials by email Literature Review of Placebo ODT trials Research Report on Placebo ODT

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)
KH-001 ODT, Placebo ODT - Premature Ejaculation
Phase 2RecruitingKadence Bio402025-12-012026-08-12
The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy
CBD Oral Disintegrating Tablet (ODT), Placebo ODT - Pain, Postoperative
Phase 2 / Phase 3CompletedNYU Langone Health1002020-12-012023-03-07
A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.
FLX-787-ODT (orally disintegrating tablet), Placebo ODT - Charcot-Marie-Tooth Disease
Phase 2TerminatedFlex Pharma, Inc.272017-10-162018-08-29
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.
FLX-787-ODT (orally disintegrating tablet), Placebo ODT - Motor Neuron Disease
Phase 2TerminatedFlex Pharma, Inc.542017-07-282018-08-29
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
FE 201836, Desmopressin, Placebo oral solution - Nocturia
Phase 2CompletedFerring Pharmaceuticals3022017-07-272022-03-02

Conditions studied

Muscle Cramp (2)  ·  Nervous System Diseases (2)  ·  Neurodegenerative Diseases (2)  ·  Neuromuscular Diseases (2)  ·  Spasm (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Charcot-Marie-Tooth Disease (1)  ·  Hereditary Sensory and Motor Neuropathy (1)  ·  Motor Neuron Disease (1)  ·  Muscular Atrophy, Spinal (1)  ·  Nervous System Malformations (1)  ·  Nocturia (1)  ·  Pain, Postoperative (1)  ·  Premature Ejaculation (1)

Sponsors

Flex Pharma, Inc. (2)  ·  Ferring Pharmaceuticals (1)  ·  Kadence Bio (1)  ·  NYU Langone Health (1)

Countries

United States (4)  ·  Australia (1)  ·  Belgium (1)  ·  Canada (1)  ·  Czechia (1)  ·  Germany (1)  ·  Hungary (1)  ·  Poland (1)

Top investigators

Bjorn Oskarsson, MD (1)  ·  Michael Alaia, MD (1)  ·  Nicolas Johnson, MD (1)

Results publications

PMID 35905305, PMID 38322981

NIH funding

2016 (1)